Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genmab A (GNMSF) EPS (Weighted Average and Diluted) (2024 - 2025)

Historic EPS (Weighted Average and Diluted) for Genmab A (GNMSF) over the last 2 years, with Q3 2025 value amounting to $32.35.

  • Genmab A's EPS (Weighted Average and Diluted) rose 1494.76% to $32.35 in Q3 2025 from the same period last year, while for Sep 2025 it was $32.35, marking a year-over-year increase of 1494.76%. This contributed to the annual value of $15.37 for FY2025, which is 1232.17% down from last year.
  • As of Q3 2025, Genmab A's EPS (Weighted Average and Diluted) stood at $32.35, which was up 1494.76% from $50.06 recorded in Q2 2025.
  • In the past 5 years, Genmab A's EPS (Weighted Average and Diluted) registered a high of $80.0 during Q1 2025, and its lowest value of $14.14 during Q1 2024.